196 related articles for article (PubMed ID: 32437721)
1. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
2. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
3. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of malignant cutaneous lymphomas].
Sterry W
Dtsch Med Wochenschr; 1988 Feb; 113(5):184-9. PubMed ID: 3276493
[No Abstract] [Full Text] [Related]
5. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
6. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma.
Ohmatsu H; Sugaya M; Suga H; Morimura S; Miyagaki T; Kai H; Kagami S; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2012 May; 92(3):282-3. PubMed ID: 22456907
[No Abstract] [Full Text] [Related]
7. Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma.
McGirt LY; Baerenwald DA; Vonderheid EC; Eischen CM
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2269-71. PubMed ID: 24909834
[No Abstract] [Full Text] [Related]
8. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
9. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
10. Genotyping of cutaneous T-cell lymphomas and pseudolymphomas.
Bignon YJ; Souteyrand P
Curr Probl Dermatol; 1990; 19():114-23. PubMed ID: 2404672
[No Abstract] [Full Text] [Related]
11. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
12. Response of CD30+ large cell lymphoma of skin to bexarotene.
Keun YK; Woodruff R; Sangueza O
Leuk Lymphoma; 2002 May; 43(5):1153-4. PubMed ID: 12148901
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous T-cell lymphoma].
Dippel E; Gellrich S; Klemke CD; Goerdt S; Sterry W
J Dtsch Dermatol Ges; 2003 Dec; 1(12):965-80; quiz 981-2. PubMed ID: 16285650
[No Abstract] [Full Text] [Related]
14. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
15. Report of the Committee on Pathology of Cutaneous T Cell Lymphomas.
Clendenning WE; Rappaport HW
Cancer Treat Rep; 1979 Apr; 63(4):719-24. PubMed ID: 376141
[No Abstract] [Full Text] [Related]
16. Sézary Syndrome without erythroderma featuring a CD30+ progression.
Pileri A; Filippi F; Agostinelli C; Neri I; Patrizi A
G Ital Dermatol Venereol; 2019 Aug; 154(4):494-495. PubMed ID: 31251008
[No Abstract] [Full Text] [Related]
17. Cyclosporine in the treatment of cutaneous T cell lymphoma.
Street ML; Muller SA; Pittelkow MR
J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
[TBL] [Abstract][Full Text] [Related]
18. CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma.
Prince HM
J Clin Oncol; 2015 Nov; 33(32):3691-6. PubMed ID: 26392103
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
